Article

FDA Briefs - March 1, 2002

Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Related Videos
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Related Content
Myopia onset predicted by accelerated eye changes a year in advance
April 2nd 2025

Myopia onset predicted by accelerated eye changes a year in advance

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award
March 15th 2025

ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

The search for an antifibrotic drug for use with pediatric glaucoma devices
March 5th 2025

The search for an antifibrotic drug for use with pediatric glaucoma devices

AI and eye tracking: Technological companions to assess amblyopia in pediatric patients
March 3rd 2025

AI and eye tracking: Technological companions to assess amblyopia in pediatric patients

© 2025 MJH Life Sciences

All rights reserved.